h5n1 strain
Recently Published Documents


TOTAL DOCUMENTS

12
(FIVE YEARS 0)

H-INDEX

6
(FIVE YEARS 0)

2014 ◽  
Vol 39 (3) ◽  
pp. 443-451 ◽  
Author(s):  
Murugan Subathra ◽  
Ponsekaran Santhakumar ◽  
Mangamoori Lakshmi Narasu ◽  
Syed Sultan Beevi ◽  
Sunil K Lal

Vaccine ◽  
2009 ◽  
Vol 27 (29) ◽  
pp. 3862-3869 ◽  
Author(s):  
Junbao Yang ◽  
John A. Gebe ◽  
Laurie Huston ◽  
Eddie James ◽  
Venus Tan ◽  
...  

2009 ◽  
Vol 83 (10) ◽  
pp. 5192-5203 ◽  
Author(s):  
Josef Mayrhofer ◽  
Sogue Coulibaly ◽  
Annett Hessel ◽  
Georg W. Holzer ◽  
Michael Schwendinger ◽  
...  

ABSTRACT The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic. Our aim was first to develop a safe live vaccine which induces both humoral and cell-mediated immune responses against human H5N1 influenza viruses and second, since the supply of embryonated eggs for traditional influenza vaccine production may be endangered in a pandemic, an egg-independent production procedure based on a permanent cell line. In the present article, the generation of a complementing Vero cell line suitable for the production of safe poxviral vaccines is described. This cell line was used to produce a replication-deficient vaccinia virus vector H5N1 live vaccine, dVV-HA5, expressing the hemagglutinin of a virulent clade 1 H5N1 strain. This experimental vaccine was compared with a formalin-inactivated whole-virus vaccine based on the same clade and with different replicating poxvirus-vectored vaccines. Mice were immunized to assess protective immunity after high-dose challenge with the highly virulent A/Vietnam/1203/2004(H5N1) strain. A single dose of the defective live vaccine induced complete protection from lethal homologous virus challenge and also full cross-protection against clade 0 and 2 challenge viruses. Neutralizing antibody levels were comparable to those induced by the inactivated vaccine. Unlike the whole-virus vaccine, the dVV-HA5 vaccine induced substantial amounts of gamma interferon-secreting CD8 T cells. Thus, the nonreplicating recombinant vaccinia virus vectors are promising vaccine candidates that induce a broad immune response and can be produced in an egg-independent and adjuvant-independent manner in a proven vector system.


2007 ◽  
Vol 51 (8) ◽  
pp. 2965-2968 ◽  
Author(s):  
Alison Budd ◽  
Lisa Alleva ◽  
Mohammed Alsharifi ◽  
Aulikki Koskinen ◽  
Victoria Smythe ◽  
...  

ABSTRACT Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (n = 46) (P = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.


Science ◽  
2006 ◽  
Vol 314 (5800) ◽  
pp. 742-742 ◽  
Author(s):  
D. Normile

Sign in / Sign up

Export Citation Format

Share Document